Social networks and pharma $

Christina Farr:

Throughout the presentation, Snap presented itself as the platform that doesn’t garner as much negativity in its culture and its comments as Facebook and Twitter. The idea is that Snap is a more comfortable place for users to talk about their sensitive health conditions, ranging from excessive sweating to sexually transmitted infections.

But the lack of negativity might also have another benefit: Unlike other advertisers on social media, pharma companies must report any adverse events about their drugs to federal agencies. That includes comments spread on social media. A more positive social media culture could mean fewer complaints to report, especially if the ads are set up in a format so that users don’t have a space to leave comments.

Snap also makes the pitch that its app is more likely to involve content that is shared between close friends, which opens up opportunities to talk about personal issues and serve them ads.

The company pointed to particular diseases that Snapchat users are “more likely to treat and diagnose,” including arthritis, asthma, diabetes and migraines, according to third-party survey data it cites from the marketing firm Global Web Index Insights. It’s unclear whether that’s in comparison to other social media tools or the general population. The company did point to its youth-focused audience and the parents who use it, saying that 34 percent of its 81 million daily North American users are between 18 and 24, and another 26 percent are 25 to 34.
Snap showed examples of previous ad campaigns. One ad to promote a drug from the pharma company Dermira that helps with excessive sweating through images of millennials jumping in the air wearing loose, summery clothing with revealing sweat patches. The slogan for that campaign, “you’re not alone,” was an attempt to reduce stigma related to the condition.